The clinical hurdles to prescribing CGM

October 31, 2014– Interviewed by Steven E. Greer, MD

The portion of total Type 1 diabetes patients who use continuous glucose monitors (CGM) are still far less than 50%. We interviewed  the CEO of Dexcom, Terry Gregg, with diabetes expert Jay Skyler, MD, from Miami, to discuss the clinical hurdles to prescribing CGM.

Disclaimer: Dr. Skyler has various relationships with Dexcom.

This entry was posted in - Medical Devices, CMS, Diabetes and endocrinology. Bookmark the permalink.

Leave a Reply

Your email address will not be published.